DK3319987T3 - Nye p450-bm3-varianter med forbedret aktivitet - Google Patents

Nye p450-bm3-varianter med forbedret aktivitet Download PDF

Info

Publication number
DK3319987T3
DK3319987T3 DK16821779.2T DK16821779T DK3319987T3 DK 3319987 T3 DK3319987 T3 DK 3319987T3 DK 16821779 T DK16821779 T DK 16821779T DK 3319987 T3 DK3319987 T3 DK 3319987T3
Authority
DK
Denmark
Prior art keywords
variants
new
improved activity
activity
improved
Prior art date
Application number
DK16821779.2T
Other languages
English (en)
Inventor
Robert Osborne
Vesna Mitchell
Khin Yu Naing Htwe
Xiyun Zhang
Erika M Milczek
Jeffrey C Moore
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Application granted granted Critical
Publication of DK3319987T3 publication Critical patent/DK3319987T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H05K999/99—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group
DK16821779.2T 2015-07-07 2016-06-02 Nye p450-bm3-varianter med forbedret aktivitet DK3319987T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189281P 2015-07-07 2015-07-07
PCT/US2016/035399 WO2017007547A1 (en) 2015-07-07 2016-06-02 Novel p450-bm3 variants with improved activity

Publications (1)

Publication Number Publication Date
DK3319987T3 true DK3319987T3 (da) 2021-06-21

Family

ID=57686072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16821779.2T DK3319987T3 (da) 2015-07-07 2016-06-02 Nye p450-bm3-varianter med forbedret aktivitet

Country Status (8)

Country Link
US (7) US9683220B2 (da)
EP (1) EP3319987B1 (da)
JP (1) JP6691558B2 (da)
CN (1) CN108271374B (da)
CA (1) CA2991195C (da)
DK (1) DK3319987T3 (da)
IL (1) IL256441B (da)
WO (1) WO2017007547A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3167052T3 (da) 2014-07-09 2020-02-10 Codexis Inc P450-bm3-varianter med forbedret aktivitet
CA2991195C (en) 2015-07-07 2021-06-29 Codexis, Inc. Novel p450-bm3 variants with improved activity
EP3370733B1 (en) * 2015-11-02 2021-07-14 Board of Regents, The University of Texas System Methods of cd40 activation and immune checkpoint blockade
WO2019183358A2 (en) 2018-03-21 2019-09-26 University Of Florida Research Foundation, Incorporated Whole cell processes to produce nitroaromatics

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
CA2191718A1 (en) 1994-06-03 1995-12-14 Randy M. Berka Phosphonyldipeptides useful in the treatment of cardiovascular diseases
EP0777737B1 (en) 1994-06-30 2005-05-04 Novozymes Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
US5483345A (en) 1994-09-06 1996-01-09 Mrs Technology, Inc. Alignment system for use in lithography utilizing a spherical reflector having a centered etched-on projection object
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
GB2306485B (en) * 1995-11-01 1998-12-09 British Gas Plc Enzyme mutant
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
EP2261373A3 (en) 1997-01-17 2011-12-14 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1999029902A1 (en) 1997-12-08 1999-06-17 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1108783A3 (en) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonucleotide-mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
WO2000052155A2 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
WO2001075767A2 (en) 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
DK1493027T3 (da) 2002-03-01 2014-11-17 Codexis Mayflower Holdings Llc Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler
US7620500B2 (en) 2002-03-09 2009-11-17 Maxygen, Inc. Optimization of crossover points for directed evolution
WO2005017105A2 (en) * 2003-06-17 2005-02-24 California University Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome p450
GB0403992D0 (en) 2004-02-23 2004-03-31 Isis Innovation Oxidation by hydrogen peroxide
CN1273585C (zh) * 2004-11-29 2006-09-06 浙江大学 细胞色素 p450bm－3 单加氧酶变体基因及其用途
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
AU2007299764B2 (en) 2006-09-22 2011-10-13 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors
MX2009003410A (es) 2006-09-29 2009-07-17 Idenix Pharmaceuticals Inc Fosfoindoles enantiomericamente puros como inhibidores de vih.
US8101399B2 (en) * 2006-12-12 2012-01-24 The Regents Of The University Of California Artemisinic epoxide and methods for producing same
US20080268517A1 (en) * 2007-02-08 2008-10-30 The California Institute Of Technology Stable, functional chimeric cytochrome p450 holoenzymes
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
GB0719620D0 (en) * 2007-10-08 2007-11-14 Isis Innovation Mutant Enzymes
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
WO2009152336A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
EP2426198A1 (en) * 2010-09-03 2012-03-07 B.R.A.I.N. Biotechnology Research And Information Network AG Cytochrome P450 monooxygenase variants
WO2012109586A2 (en) * 2011-02-11 2012-08-16 University Of Rochester Methods and systems for evaluating and predicting the reactivity of monooxygenase enzymes
WO2013076258A2 (en) * 2011-11-23 2013-05-30 Dsm Ip Assets B.V. P450 bm3 mutants and their use for regio- and stereoselective hydroxylation of alpha-and beta-ionone
CN102757944A (zh) * 2012-07-24 2012-10-31 浙江大学宁波理工学院 细胞色素p450bm-3(d168l/e435t)变体酶及其编码基因和用途
JP2015534464A (ja) * 2012-10-09 2015-12-03 カリフォルニア インスティチュート オブ テクノロジー ヘム酵素によって触媒されるインビボおよびインビトロオレフィンシクロプロパン化
DK3167052T3 (da) 2014-07-09 2020-02-10 Codexis Inc P450-bm3-varianter med forbedret aktivitet
CA2991195C (en) * 2015-07-07 2021-06-29 Codexis, Inc. Novel p450-bm3 variants with improved activity

Also Published As

Publication number Publication date
CN108271374A (zh) 2018-07-10
US10704030B2 (en) 2020-07-07
CA2991195C (en) 2021-06-29
JP2018520674A (ja) 2018-08-02
US20210214694A1 (en) 2021-07-15
EP3319987A1 (en) 2018-05-16
US20190024059A1 (en) 2019-01-24
US10113153B2 (en) 2018-10-30
US20170247667A1 (en) 2017-08-31
US20170009213A1 (en) 2017-01-12
US20200291365A1 (en) 2020-09-17
CA2991195A1 (en) 2017-01-12
EP3319987A4 (en) 2018-12-19
WO2017007547A1 (en) 2017-01-12
JP6691558B2 (ja) 2020-04-28
US11591578B2 (en) 2023-02-28
US9683220B2 (en) 2017-06-20
US10450550B2 (en) 2019-10-22
CN108271374B (zh) 2021-09-21
US20200002685A1 (en) 2020-01-02
US10982197B2 (en) 2021-04-20
IL256441B (en) 2020-02-27
EP3319987B1 (en) 2021-05-05
IL256441A (en) 2018-02-28
US20230250403A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
DK3240773T3 (da) Picolinamidforbindelser med fungicid aktivitet
DK3190923T3 (da) Hovedstøtte
DK3332005T3 (da) Promotorvarianter
FR3019749B1 (fr) Autoinjecteur
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3174483T3 (da) Hyporørkonstruktion
DK3167052T3 (da) P450-bm3-varianter med forbedret aktivitet
KR20180084915A (ko) 구조체
DK3337795T3 (da) Piperidinobenzodiazepinforbindelser med anti-proliferativ aktivitet
DK3203834T3 (da) Hovbehandlingsarrangement
DK3310914T3 (da) Chymosinvarianter med forbedrede egenskaber
DK3298022T3 (da) Nye annelerede phenoxyacetamider
FI20145185A (fi) Liikkeenrajoitinrakenne
IL256441B (en) New p450–bm3 variants with enhanced activity
DK3380552T3 (da) BCHPC med reduceret brændhastighed
DK3370794T3 (da) Antimikrobielle opløsninger med forbedret stabilitet
FI20145032A (fi) Nasta
DK3193936T3 (da) Antimikrobielle midler med forøget virkning
DK3313999T3 (da) Polypeptider med demethyleringsaktivitet
DK3390621T3 (da) Forbedret fermentering
DK3097084T3 (da) Nye kallikrein 7-hæmmere
DK3096613T3 (da) Forbedret måttestruktur med insekticid
FR3020631B1 (fr) Cabestan
ITUA20162175A1 (it) Stimolatore clitorideo
FI11555U1 (fi) Valvontajärjestely